Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04936308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

Name: Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent — clinical trial record (NCT04936308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SOLSTICE

StatusCompleted

PhasePhase 3

SponsorJanssen Research & Development, LLC

Started2021-09-28

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.

Amendment history 1 change detected by DataLookout

2026-08-21

Trial completed

Trial Details

NCT Number	NCT04936308
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Arthritis, Psoriatic
Enrollment	453 participants
Start Date	2021-09-28
Primary Completion	2024-10-28 (estimated)
Study Completion	2026-07-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-20